The DESI1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9?edited polyclonal knockout population derived from Raji B lymphocytes, designed to abrogate DESI1 gene function. This pooled format avoids clonal selection artifacts and enables stable, population?level interrogation of DESI1?mediated deSUMOylation, providing a physiologically relevant loss?of?function system for studying SUMO?dependent regulation in a lymphoblastoid setting.
The Raji host cell line is an Epstein?Barr virus (EBV)?positive Burkitt lymphoma model that maintains the viral genome in a type III latency program. These cells express latency proteins such as LMP1 and EBNA2, driving constitutive NF???B and pro?survival signaling, making them a benchmark for immunological studies, viral oncogenesis, and B?cell malignancy research.
DESI1 functions as a cysteine protease that specifically hydrolyzes the isopeptide bond between SUMO proteins and lysine residues on target substrates, thereby reversing SUMOylation. Key deSUMOylated targets include the promyelocytic leukemia protein (PML), SP100, p53, and the NF???B inhibitor I??B??. Through these substrates, DESI1 modulates critical cellular pathways: it influences PML nuclear body assembly and DNA damage responses, controls p53 stability and transcriptional activity, and regulates NF???B signaling by deconjugating SUMO from I??B??. The enzyme interacts with SUMO1 and SUMO2/3 isoforms, the E2 enzyme UBC9, and shares functional overlap with the SENP1 protease. Its expression and activity are regulated by upstream transcriptional cues and cellular stress, placing DESI1 at the intersection of genotoxic stress signaling, apoptosis, and gene expression networks.
In the Raji model, disruption of DESI1 enables systematic analysis of how deSUMOylation contributes to EBV?associated lymphomagenesis. Aberrant SUMO modification of PML bodies, p53, and I??B?? has been linked to viral latency maintenance, proliferation, and resistance to apoptosis. Therefore, this knockout cell population offers a pertinent tool to dissect DESI1??s role in sustaining the transformed phenotype, regulating EBV reactivation, and mediating response to chemotherapeutic agents.
Researchers can employ this model for a broad array of experimental strategies: Western blotting to monitor global SUMO conjugate profiles, co?immunoprecipitation to capture specific DESI1 substrates, immunofluorescence microscopy to visualize PML?body dynamics, and enzymatic assays to measure deSUMOylase activity. Functional endpoints such as apoptosis and proliferation assays, combined with transcriptomic analysis via RNA?seq, can reveal downstream gene expression changes. Additionally, the polyclonal population is suitable for high?throughput inhibitor screening targeting the deSUMOylation machinery. These cells provide a versatile platform for both fundamental research into SUMO biology and translational studies in Burkitt lymphoma. For further details, please contact Ascent Research.
